Grace Therapeutics, Inc. (GRCE) stock
GRCENasdaqPharmaceutical PreparationsFiscal year ends March 31
$1.81−0.04 (-2.43%)
Close on Nov 12, 2026Market cap $38.08MP/E –Yield –
Earnings
Grace Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Nov 12, 2026
Q2 FY2027 · estimated, before the open
Revenue, Q1 FY2027
–
EPS, Q1 FY2027
-$0.91
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of Grace Therapeutics's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q2 FY2027ended Sep 30, 2026 | Nov 12, 2026Expected | – | – | – | – |
| Q1 FY2027ended Jun 30, 2026 | Aug 13, 2026before the open | – | – | -$0.91 | Release |
| Q4 FY2026ended Mar 31, 2026 | Jun 18, 2026before the open | – | – | – | Release |
| Q3 FY2026ended Dec 31, 2025 | Feb 12, 2026before the open | – | – | -$0.14 | Release |
| Q2 FY2026ended Sep 30, 2025 | Nov 13, 2025before the open | – | – | -$0.06 | Release |
| Q1 FY2026ended Jun 30, 2025 | Aug 12, 2025before the open | – | – | – | Release |
| Q4 FY2025ended Mar 31, 2025 | Jun 23, 2025before the open | – | – | – | Release |
| Q3 FY2025ended Dec 31, 2024 | Feb 13, 2025before the open | – | – | -$0.36 | Release |
| Q2 FY2025ended Sep 30, 2024 | Nov 13, 2024before the open | – | – | -$0.30 | Release |
| Q1 FY2025ended Jun 30, 2024 | Aug 9, 2024before the open | – | – | -$0.24 | Release |
| Q4 FY2024ended Mar 31, 2024 | Jun 21, 2024before the open | – | – | – | Release |
| Q3 FY2024ended Dec 31, 2023 | Feb 12, 2024before the open | – | – | -$0.21 | Release |
| Q2 FY2024ended Sep 30, 2023 | Nov 13, 2023before the open | – | – | -$0.43 | Release |
| Q1 FY2024ended Jun 30, 2023 | Aug 11, 2023before the open | – | – | -$0.54 | Release |
| Q4 FY2023ended Mar 31, 2023 | Jun 23, 2023before the open | – | – | – | Release |
| Q3 FY2023ended Dec 31, 2022 | Feb 14, 2023before the open | – | – | -$0.09 | Release |
| Q2 FY2023ended Sep 30, 2022 | Nov 14, 2022before the open | – | – | -$0.11 | Release |
| Q1 FY2023ended Jun 30, 2022 | Aug 11, 2022before the open | – | – | -$0.10 | Release |
| Q4 FY2022ended Mar 31, 2022 | Jun 21, 2022before the open | – | – | – | Release |
| Q3 FY2022ended Dec 31, 2021 | Feb 14, 2022before the open | – | – | -$0.09 | Release |
| Q2 FY2022ended Sep 30, 2021 | Nov 10, 2021before the open | – | – | $0.03 | Release |
| Q1 FY2022ended Jun 30, 2021 | Aug 12, 2021during market hours | – | – | – | Filing |
| Q4 FY2021ended Mar 31, 2021 | Jun 22, 2021before the open | – | – | – | Filing |
| Q3 FY2021ended Dec 31, 2020 | Feb 9, 2021after the close | – | – | – | Filing |
| Q2 FY2021ended Sep 30, 2020 | Nov 16, 2020before the open | – | – | – | Filing |
| Q1 FY2021ended Jun 30, 2020 | Aug 13, 2020before the open | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
Grace Therapeutics has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When Grace Therapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases Grace Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- News
- News
- News
- News
- Results
- News
- News
- Results
- Results
- Results
- News
- News
- News
See a number that looks wrong?